Openbookopenbook
Equity
ALNY
+0.0 · +0.00%
USD · NASDAQ

Alnylam Pharmaceuticals Inc(ALNY) Stock Analysis | Healthcare

USD --+0.00%
Reward72High
Risk14Low
75%Data
Strong 16% profit margin · Revenue growing 67% YoY
Quality Compounder
Market Cap:31.61Bn
ⓘ
Reward Rating
72
High
Reward Assessment
75% data coverage
Top 25% of stocksView factors
ⓘ
Risk Rating
14
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALNY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ALNY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $370.20.

What is Alnylam Pharmaceuticals Inc?

discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

ALNY · Verdict

Strong reward · low risk

ALNY stands out on volatility and growth, but watch the valuation signal.

Based on 88% data coverage

ALNY · Verdict

What’s working & what to watch

Strengths 5

  • Volatility95/100

    Top decile vs peers

  • Growth92/100

    Revenue +53.0% CAGR

  • Profitability83/100

    8% net margin · 97% ROE

  • Cash flow82/100

    13% free-cash-flow margin

  • Balance sheet78/100

    Interest covered 2.3×

Watchouts 1

  • Valuation44/100

    P/E 26.4× · PEG 0.44

Model-based scoring. For information only — not financial advice.

What is Alnylam Pharmaceuticals Inc?

discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 31.61B, and a P/E ratio of 41.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (72)

The scoring profile indicates a strong reward potential, driven primarily by growth and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

RPRXLarge Cap / 33.9B market cap
Royalty Pharma Plc
Compare
BNTXLarge Cap / 29.3B market cap
BioNTech SE
Compare
INSMLarge Cap / 27.5B market cap
Insmed Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap31.61B
P/E Ratio41.1533
Dividend YieldN/A
Beta0.279
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
921,255 shares
$6.9M
0
6-9months
1135,068 shares
$11.9M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.